AFFX Affymetrix, Inc.

Affymetrix Inc. (Nasdaq:AFFX) and Baylor College of Medicine announced today that Baylor has obtained a non-exclusive, worldwide license to a number of Affymetrix patents covering comparative genomic hybridization (CGH) microarray services in Clinical Laboratory Improvement Amendments (CLIA) environments. Financial details of the license were not disclosed. �Since the inception of our licensing program, Affymetrix has�signed many agreements that validate our position as�the�clear market�innovator and�leader,� said Alan Sherr, vice president and chief counsel for Licensing at Affymetrix. �This agreement with Baylor College of Medicine is another example of a mutually beneficial relationship that enables both companies to better serve customers within the growing microarray market.� �Comparative genomic hybridization microarrays represent one of the biggest advancements of the last 30 years in clinical genetic laboratory testing. The technology is being used to identify specific genetic abnormalities in many children that have developmental disabilities with previously unknown causes,� said Arthur Beaudet,�M.D., professor and chairman of the Department of Molecular and Human Genetics at Baylor College of Medicine. About Baylor College of Medicine Baylor College of Medicine in Houston, the only private medical school in the Greater Southwest, was founded in 1900 and is today an internationally respected medical and research institution known for excellence in education, research and patient care. For more information about Baylor College of Medicine, please visit the company's website at http://www.bcm.edu. About Affymetrix Affymetrix scientists invented the world's first high-density microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip� technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,400 systems have been installed around the world and more than 7,000 peer-reviewed papers have been published using the technology. Affymetrix' patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyzing the relationship between genetics and health. Affymetrix is headquartered in Santa Clara, Calif., with manufacturing facilities in Sacramento, Calif., and Bedford, Mass. The company maintains important sales and marketing operations in Europe and Asia and has about 1,100 employees worldwide. For more information about Affymetrix, please visit the company's website at www.affymetrix.com. All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties relating to commercial success of the licensing agreement with Baylor College of Medicine discussed in this press release; risks of the Company's ability to achieve and sustain higher levels of revenue, higher gross margins, reduced operating expenses; uncertainties relating to technological approaches, manufacturing, product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties relating to sole source suppliers; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix' Form 10-K/A for the year ended December 31, 2005, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks owned or used by Affymetrix Inc. Affymetrix Inc. (Nasdaq:AFFX) and Baylor College of Medicine announced today that Baylor has obtained a non-exclusive, worldwide license to a number of Affymetrix patents covering comparative genomic hybridization (CGH) microarray services in Clinical Laboratory Improvement Amendments (CLIA) environments. Financial details of the license were not disclosed. "Since the inception of our licensing program, Affymetrix has signed many agreements that validate our position as the clear market innovator and leader," said Alan Sherr, vice president and chief counsel for Licensing at Affymetrix. "This agreement with Baylor College of Medicine is another example of a mutually beneficial relationship that enables both companies to better serve customers within the growing microarray market." "Comparative genomic hybridization microarrays represent one of the biggest advancements of the last 30 years in clinical genetic laboratory testing. The technology is being used to identify specific genetic abnormalities in many children that have developmental disabilities with previously unknown causes," said Arthur Beaudet, M.D., professor and chairman of the Department of Molecular and Human Genetics at Baylor College of Medicine. About Baylor College of Medicine Baylor College of Medicine in Houston, the only private medical school in the Greater Southwest, was founded in 1900 and is today an internationally respected medical and research institution known for excellence in education, research and patient care. For more information about Baylor College of Medicine, please visit the company's website at http://www.bcm.edu. About Affymetrix Affymetrix scientists invented the world's first high-density microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip(R) technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,400 systems have been installed around the world and more than 7,000 peer-reviewed papers have been published using the technology. Affymetrix' patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyzing the relationship between genetics and health. Affymetrix is headquartered in Santa Clara, Calif., with manufacturing facilities in Sacramento, Calif., and Bedford, Mass. The company maintains important sales and marketing operations in Europe and Asia and has about 1,100 employees worldwide. For more information about Affymetrix, please visit the company's website at www.affymetrix.com. All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties relating to commercial success of the licensing agreement with Baylor College of Medicine discussed in this press release; risks of the Company's ability to achieve and sustain higher levels of revenue, higher gross margins, reduced operating expenses; uncertainties relating to technological approaches, manufacturing, product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties relating to sole source suppliers; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix' Form 10-K/A for the year ended December 31, 2005, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks owned or used by Affymetrix Inc.